Professional Documents
Culture Documents
Todays issue of PD
Pharmacy Daily today has
Codeine stockpiling alert Guild slams News Ltd
THe Pharmacy Guild has
The Victorian the practice could responded swiftly to New Limited
three pages of news plus a full Pharmacy Authority spread, the VPA articles published earlier this week
page from MIMS. (VPA) has issued said, reminding which claimed greedy chemists
a formal warning pharmacists they are forcing patients to pay more
Hail to the King about consumers must personally by denying them the optional
Federal Shadow Health attempting deliver or personally $1 discount on PBS prescription
Minister Catherine King will to stockpile supervise the supply copayments.
deliver a keynote address at S3 medicines of any S3 product, The Guild has in the past noted
the Pharmaceutical Society of containing codeine, in the lead-up and provide directions for its use. that offering the $1 discount simply
Communiqu means patients reach the safety net
Australias upcoming PSA17 annual to the rescheduling of the products Relevantly, the supply must be
conference taking place in Sydney. as prescription only next year.
31 March 2017 for therapeutic use after taking all threshold more slowly, with the net
King will speak on Fri 28 Jul and In a circular to pharmacists the reasonable steps to ensure that effect the same.
highlight the Labor Partys National VPA said the decisionTheto transfer a therapeutic
Victorian Pharmacy need
Authority (theexists, the met on 14InMarch
Authority) this latest
2017stoush, Guild
at the Authority offices.
Health Platform and vision for the non-prescription medicines that Authority added. executive director David Quilty has
pharmacy sector ahead of the contain codeine into Schedule 4
Recent Panel MEANWHILE the VPA also noted
Hearings written to the editors of the various
next Federal Election. has generated attempts by codeine serious common deficiencies newspapers, saying the claims by
PSA national vice president said habitus to use agentsThe Victorian Pharmacy Authority held two panel hearingsreporter
to purchase highlighted during inspections of in February Sue 2017.
Dunlevy are incorrect.
the Society was pleased to hear of stocks of them for reward.
Hearing 1 pharmacies in the state, including On the contrary, pharmacies are
Labors commitment to honour the The Authority cited an allegation a failure to routinely scan all working in partnership with the
Two pharmacists in partnership were reprimanded for carrying Federalon a pharmacytobusiness
Government without
deliver very
6CPA during Kings speech at the where a person had used an on- dispensed medicines.
premises being registered and without the owners having been granted a licence to carry on
recent APP conference, as well as line marketplace to recruit people
business Given theThe
at those premises. well-known
owners had problems large medicine
lodged the appropriate price reductions
applications of to sub
but failed
a promise of early and inclusive to visit pharmacies andthepurchase associated
required notifications andwith look-alike
pay the sound-
associated 50%
registration andor licence
more through
fees. PBS reforms.
negotiations towards the Seventh items such as Nurofen Plus and alike products as well as selection The low take-up of the optional
Community Pharmacy Agreement. Comment.
place them in a letterbox, with a Licensing of eligible
errors persons
and storing to carry
products, $1 discount
on a pharmacy
where simply
business andreflects the fact
registration of premi
are cornerstones of the Pharmacy Regulation Act 2010 and are fundamental to the legislative reg
PSA17 will also include an commission paid to the agent. the first few letters are the same, it that the sickest patients understand
and the Authoritys policies and guidelines. These are in the public interest as their absence undermi
appearance by pharmacist and The Glen Waverley area has
the suitability is surprising
of premises andthat
thesome of pharmacythere
pharmacists
practice is no net
in Victoria. benefit
The for them21)
Act (section as provi
former Australian Comic of the been identified at the penalties
time of of 240 penalty
do notunits
take (approx.
full advantage
$37,300) in the caseit of
of the means theyperson
a natural take longer to reach
and 1,200 penalty u
Year, Marty Wilson - psa17.com. this Circular going to press, but$186,500)
(approx. scanning technology,
in the case of a bodythe VPA said.In thistheir
corporate. casePBStheSafety Net, Quilty
pharmacists wrote.on oth
had relied
to submit the required notifications and highlights that owners are ultimately responsible for ensu
legislative requirements are met.
Hearing 2
NEW
RRP Two pharmacists in partnership were cautioned in that following an inspection, there were failures:
Breath-A-Tech
(a) in recording accurately all transactions of Schedule 8 poisons;
$149.95 Pocket Air and Controlled Substan
(b) in storing methadone in accordance with the Drugs, Poisons
Regulations 2006; Portable Nebuliser
(c) to maintain a temperature data logger in accordance with the Authoritys Guidelines;
Used in Australian (d) in keeping records of transactions of Schedule 8 poisons in a timely manner;
Pharmacies, Hospitals (e) in restricting the display of Schedule 3 poisons containing codeine to one shelf facing of
and Medical Centres smallest commercial package of each product in accordance with the Authoritys Guideline
$29.95
Comment. There were two general aspects to this hearing. The first (a to f) centres on p
housekeeping and regulatory deficiencies and the second (g) on making a false certification on
inspection report that is returned to the Authority.
The Authority wishes to make clear that it views false certifications seriously. Certifying an inspec
Breath-A-Tech Spacer & Maskreport is not a mere formality. The licensee or a person authorised by the licensee usually
Combo packs pharmacist regularly and usually in charge must ensure that all deficiencies listed in the report h
For orders and more information please call your Pharmabroker representative or Wholesaler
Always read the label. Use only as directed. If symptoms persist, see your doctor/healthcare professional
Pharmacy Daily Thursday 4th May 2017 t 1300 799 220 w www.pharmacydaily.com.au page 1
The long and the short of pharmacy
Gold Coast
pharmacist Veronica
Moss is celebrating
after being named the
PSA MIMS Queensland
Intern Pharmacist of
Thursday 04 May 2017 the Year.
Moss (pictured) was
Corner
Pharmaceutical Sciences
Pharmacy Daily is Australias favourite pharmacy industry publication. Publisher/Editor in chief: Bruce Piper Editorial: info@pharmacydaily.com.au
Sign up free at www.pharmacydaily.com.au. Managing Editor: Jon Murrie
Postal address: PO Box 1010, Epping, NSW 1710 Australia Reporter: Mal Smith
Street address: Level 2, Suite 1 64 Talavera Rd, Macquarie Park NSW 2113 Australia Contributors: Matt Bell, Rebecca Le Bas, Jasmine ODonoghue
Advertising and Marketing: Sean Harrigan and Melanie Tchakmadjian advertising@pharmacydaily.com.au
P: 1300 799 220 (+61 2 8007 6760) F: 1300 799 221 (+61 2 8007 6769)
Business Manager: Jenny Piper accounts@pharmacydaily.com.au
Part of the Business Publishing Group.
business events news
Pharmacy Daily is a publication of Pharmacy Daily Pty Ltd ABN 97 124 094 604. All content fully protected by copyright. Please obtain written permission to reproduce any material. While every care has been taken in the preparation of
the newsletter no liability can be accepted for errors or omissions. Information is published in good faith to stimulate independent investigation of the matters canvassed. Responsibility for editorial comment is taken by Bruce Piper.
Pharmacy Daily Thursday 4th May 2017 t 1300 799 220 w www.pharmacydaily.com.au page 3
May 2017
New Products
Belkyra (deoxycholic acid) is a formulation of synthetically derived deoxycholic acid. Deoxycholic acid is a cytolytic drug, which
when injected into localised subcutaneous fat, physically disrupts the cell membrane of adipocytes and causes cell lysis.
Macrophages are attracted to the area to eliminate cellular debris and lipids, followed by the appearance of fibroblasts and observed
thickening of fibrous septa. Belkyra injection is indicated for improvement in the appearance of moderate to severe convexity or
fullness associated with submental fat in adults. Belkyra is contraindicated in the presence of infection in the treatment area. Belkyra
10 mg/mL solution for injection is supplied in single use 2 mL vials in packs of 4s.
Epiduo Forte (adapalene/ benzoyl peroxide) combines two active substances which act through different but complementary
mechanisms of action. Topical adapalene normalises the differentiation of follicular epithelial cells resulting in decreased
microcomedone formation. Benzoyl peroxide has antimicrobial and sebostatic activity in acne, and additionally exfoliative and
keratolytic activities acting against comedones at all stages of development. Epiduo Forte is indicated for cutaneous treatment of
acne vulgaris, when comedones, numerous papules and pustules are present in patients 12 years of age and older and the
condition has not responded to first line treatment. Epiduo Forte (adapalene 0.3%/ benzoyl peroxide 2.5%) topical gel is supplied as
a 30 g bottle with pump.
Grazax (Timothy grass pollen (Phleum pratense) allergen extract) modifies the immune response to grass pollen induced
allergic disease, leading to improvement in disease control and quality of life during subsequent natural allergen exposure. Grazax
is indicated for disease modifying treatment of grass pollen (P. pratense or allergens cross reacting with P. pratense) induced
allergic rhinitis with or without conjunctivitis in adults, adolescents and children above the age of 5 years. Grazax is contraindicated
in adults with uncontrolled asthma or FEV1 < 70% of predicted value (after adequate pharmacological treatment) at initiation of
treatment; in paediatric patients with uncontrolled asthma or FEV1 < 80% of predicted value (after adequate pharmacological
treatment) at initiation of treatment; in patients with malignant or systemic disease affecting the immune system (e.g. autoimmune
diseases, immune complex diseases or immune deficiency diseases); in patients with acute severe oral inflammation or oral
wounds. Grazax is supplied as 75,000 SQ-T tablets in packs of 30s.
Stivarga (regorafenib) is an oral antitumour agent that potently blocks multiple protein kinases, including kinases involved in
tumour angiogenesis (VEGFR1, 2, 3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF), and the tumour microenvironment (PDGFR,
FGFR). In particular, regorafenib inhibits mutated KIT, a major oncogenic driver in gastrointestinal stromal tumours (GIST) and
thereby blocks tumour cell proliferation. Stivarga is indicated for the treatment of metastatic colorectal cancer that has been
previously treated with fluoropyrimidine, oxaliplatin and irinotecan based chemotherapy, an anti-VEGF therapy, and, if RAS wild
type, an anti-EGFR therapy. Stivarga is also indicated for the treatment of unresectable or metastatic GIST in patients who
progressed on or are intolerant to prior treatment with imatinib and sunitinib. Severe drug induced liver injury with fatal outcome has
been observed in patients receiving Stivarga. Monitor hepatic function prior to and during treatment. Stivarga is supplied as 40 mg
tablets in packs of 84s (3 x 28s).
New Indications
Afinitor (everolimus) is now indicated for the treatment of progressive, unresectable or metastatic, well differentiated,
nonfunctional neuroendocrine tumours of gastrointestinal or lung origin in adults.
Boostrix (diphtheria/ tetanus/ acellular pertussis (dTpa)) vaccine is now indicated for booster vaccination against diphtheria,
tetanus and pertussis in children aged four years and older.
Stelara (ustekinumab (rmc)) is now indicated for the treatment of adults with moderately to severely active Crohns disease who
have had an inadequate response, lost response, or were intolerant to either conventional therapy or a TNF antagonist or have
medical contraindications to such therapies.
Zydelig (idelalisib) in combination with ofatumumab is now indicated for the treatment of adults with chronic lymphocytic
leukaemia/ small lymphocytic lymphoma upon relapse in patients for whom chemo-immunotherapy is not considered suitable.
New Contraindications
Kaletra (lopinavir / ritonavir) is now contraindicated with the antipsychotic lurasidone.
This list is a summary of only some of the changes that have occurred over the last month.
Before prescribing, always refer to the full product information.